JP2024526984A - 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物 - Google Patents

増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物 Download PDF

Info

Publication number
JP2024526984A
JP2024526984A JP2024504199A JP2024504199A JP2024526984A JP 2024526984 A JP2024526984 A JP 2024526984A JP 2024504199 A JP2024504199 A JP 2024504199A JP 2024504199 A JP2024504199 A JP 2024504199A JP 2024526984 A JP2024526984 A JP 2024526984A
Authority
JP
Japan
Prior art keywords
membered
alkyl
heterocycloalkyl
independently selected
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526984A5 (https=
Inventor
グイドッチ，クリスティアーナ
ノヴィスキー，マーク
Original Assignee
ニューリックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス，インコーポレイテッド filed Critical ニューリックス セラピューティクス，インコーポレイテッド
Publication of JP2024526984A publication Critical patent/JP2024526984A/ja
Publication of JP2024526984A5 publication Critical patent/JP2024526984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024504199A 2021-07-23 2022-07-22 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物 Pending JP2024526984A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225401P 2021-07-23 2021-07-23
US63/225,401 2021-07-23
PCT/US2022/038084 WO2023004163A1 (en) 2021-07-23 2022-07-22 Bifunctional compounds for degrading btk with enhanced imid activity

Publications (2)

Publication Number Publication Date
JP2024526984A true JP2024526984A (ja) 2024-07-19
JP2024526984A5 JP2024526984A5 (https=) 2025-07-25

Family

ID=82898772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504199A Pending JP2024526984A (ja) 2021-07-23 2022-07-22 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物

Country Status (10)

Country Link
US (1) US20250017922A1 (https=)
EP (1) EP4373493A1 (https=)
JP (1) JP2024526984A (https=)
KR (1) KR20240039001A (https=)
CN (1) CN118019539A (https=)
AU (1) AU2022313210A1 (https=)
CA (1) CA3226590A1 (https=)
IL (1) IL310269A (https=)
MX (1) MX2024000947A (https=)
WO (1) WO2023004163A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2024524480A (ja) * 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CN120202200A (zh) * 2023-06-01 2025-06-24 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
WO2025162210A1 (zh) * 2024-02-04 2025-08-07 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
WO2023004163A1 (en) 2023-01-26
KR20240039001A (ko) 2024-03-26
IL310269A (en) 2024-03-01
US20250017922A1 (en) 2025-01-16
EP4373493A1 (en) 2024-05-29
MX2024000947A (es) 2024-04-12
CA3226590A1 (en) 2023-01-26
CN118019539A (zh) 2024-05-10
AU2022313210A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP2024526984A (ja) 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
US12582722B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US20240336595A1 (en) Bifunctional compounds for degrading btk with diminished imid activity
US8304423B2 (en) Modulators of muscarinic receptors
AU2014308831A1 (en) Isotopically enriched azaindoles
US7786107B2 (en) Modulators of muscarinic receptors
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250716